Induced Pluripotent Stem Cells: Global Markets - KPLC 7 News, Lake Charles, Louisiana

Induced Pluripotent Stem Cells: Global Markets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer

LONDON, July 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Induced Pluripotent Stem Cells : Global Markets

https://www.reportbuyer.com/product/2212008/Induced-Pluripotent-Stem-Cells--Global-Markets.html

This BCC Research report provides detailed market and industry analyses to help readers quantify and qualify the global market for induced pluripotent stem cells (iPSCs). Important trends of the field and market segments are identified, and market sizes and sales forecasts by segmented markets are provided through 2018. Information is presented with a specific focus on the various market segments, including product-type-based, product-function-based, application-based, geography-based and technological-method-based.

Use this report to:
- Receive comprehensive and up-to-date background on the marketplaces associated with the induced pluripotent stem cells.
- Learn about the various market segments, including product-type-based, product-function-based, application-based, geography-based and technological-method-based.
- Receive research and market trends by analyzing the funding, patent publications and sales trends of major players in the field.
- Receive profiles of leading companies in the industry.

Highlights
- The global market for induced pluripotent stem cells (iPSCs) was estimated to total $853 million in 2012, and close to $1.2 billion in 2013, averaging 40% growth. The market is expected to reach $2.9 billion in 2018, an estimated compound annual growth rate (CAGR) of 19.7% for the five-year period 2013 to 2018.
- The U.S. market was valued at $605 million in 2013 and is expected to reach nearly $1.5 billion by 2018, a CAGR of 19.4% from 2013 to 2018.
- The Asia-Pacific market was valued at $260 million in 2013 and will experience the fastest growth among all regional markets with a five-year CAGR of 22% to reach $703 million by 2018.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
The aim of this report is to provide detailed market and industry analyses to help readers quantify and qualify the global market for induced pluripotent stem cells
(iPSCs). Important trends of the field and market segments are identified, and market sizes and sales forecasts by segmented markets are provided through 2018.
This report focuses on the market side rather than the technical side. The detailed market segmentation, market shares, major drivers, trend analysis and forecasts for
the entire iPSCs market are analyzed.

REASONS FOR DOING THIS STUDY
Detailed market and industry analysis for the iPSCs market is needed. As a breakthrough technology recognized by 2012 Nobel Physiology and Medicine Prize,
iPSCs technology may bring a revolutionary change to modern medicine. Great opportunities always exist with high risks, but the detailed analysis and forecasts of the
iPSC market can provide useful information for all management levels to help make strategic decisions in related areas. iPSC-related products are forming an emerging market despite the fact that iPSC clinical applications are still under development. The potential scope of the iPSC market is becoming clear, and it is appropriate to review the emerging market, see the current size and share of each segment, evaluate the market trends and look to its future.

INTENDED AUDIENCE
This report is designed to satisfy the information needs of various individuals involved in the biological research, pharmaceutical and regenerative medicine marketplaces,
including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. It is also
aimed at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive and up-to-date background on the
marketplaces associated with the induced pluripotent stem cells with which they are operating.

This report was prepared as a study of the global market for induced pluripotent stem cells. Information is presented with a specific focus on the various market segments,
including product-type-based, product-function-based, application-based, geography-based and technological-method-based. The detailed segmentation is to
provide a deep profiling of the global iPSCs market based on which the market forecasts are made.

This study will be of significant interest to academic institutions, hospitals, biotech and pharmaceutical companies, biopharmaceutical researchers, marketing executives from pharmaceutical and biotech companies, contract research organizations, biologists, chemists, physicians, pharmaceutical directors, product managers and representatives, and all manner of institutional directors from either public or private entities. It will also be of interest to investment bankers in the biotechnology and pharmaceutical sectors, insurance executives and life sciences product marketing managers.

SCOPE OF REPORT
This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered. For example,
application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments
include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis; iPSC-derived cell-type-based market segments include
cardiomyocytes, hepatocytes, neurons, endothelia cells, and other cell types; geography-based market segments include the U.S., Europe, Asia-Pacific and Rest of
World. Research and market trends are also analyzed by analyzing the funding, patent publications and sales trends of major players in the field.

METHODOLOGY
Both primary and secondary research methodologies were used to prepare this study. Primary research includes interviews with leading individuals in stem cell companies
and industry associations. Primary sources of published data include company annual reports, SEC filings, and government and industry publications. Secondary sources
consist of literature searches, industry journals and other commercial publications. Data for market estimates and forecasts are pooled from a range of sources that were
critically assessed by BCC Research.
TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
INTENDED AUDIENCE 2
SCOPE OF REPORT 3
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYST CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 4
DISCLAIMER 4

CHAPTER 2 MARKET SUMMARY 6
KEY DRIVERS FOR MARKET GROWTH 6
SUMMARY TABLE GLOBAL INDUCED PLURIPOTENT STEM CELL MARKET BY REGION,
THROUGH 2018 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL INDUCED PLURIPOTENT STEM CELL MARKET BY
REGION, 2012-2018 ($ MILLIONS) 7

CHAPTER 3 OVERVIEW 10
INTRODUCTION 10
HISTORY AND CURRENT STATE 11
EVOLUTION OF INDUCED PLURIPOTENT STEM CELL RESEARCH 12
INDUCED PLURIPOTENT STEM CELL ADVANTAGES AND DISADVANTAGES 12
ADVANTAGES 12
DISADVANTAGES 12
TECHNOLOGY OVERVIEW 14
INDUCED PLURIPOTENT STEM CELL GENERATION 14
Retrovirus and Lentivirus 15
Adenovirus 15
Sendai Virus 15
Episomal Plasmids 16
PiggyBac 16
Minicircle Vectors 16
Synthetic mRNA 16
Protein 17
Small-Molecular Chemicals 17
INDUCED PLURIPOTENT STEM CELL DIFFERENTIATION 18
Cardiomyocytes 18
Hepatocytes 18
Neurons 19
Endothelia Cells 20

CHAPTER 4 INDUCED PLURIPOTENT STEM CELL APPLICATIONS 22
ACADEMIC RESEARCH 22
PHARMACO-TOXICOLOGICAL SCREENING 22
DRUG DISCOVERY AND DEVELOPMENT 24
DISEASE MODELING 24
TISSUE ENGINEERING 25
CELL THERAPY 26

CHAPTER 5 INDUCED PLURIPOTENT STEM CELL MARKET SEGMENTATION AND
FORECAST 28
INDUCED PLURIPOTENT STEM CELL MARKET OVERVIEW 28
FIGURE 1 GLOBAL INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET SHARES
BY REGION, 2018 (%) 28
TABLE 1 U.S. INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET BY STATE,
THROUGH 2018 ($ MILLIONS) 29
FIGURE 2 U.S. INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET SHARES BY
STATE, 2018 (%) 29
TABLE 2 METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS,
THROUGH 2018 ($ MILLIONS) 31
FIGURE 3 METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS,
MARKET SHARES, 2018 (%) 31
TABLE 3 METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS,
THROUGH 2018 ($ MILLIONS) 32
FIGURE 4 METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELL,
MARKET SHARES, 2018 (%) 32
APPLICATION-BASED MARKET OVERVIEW 33
TABLE 4 GLOBAL INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 33
FIGURE 5 GLOBAL INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET SHARES
BY APPLICATION, 2018 (%) 33
U.S. INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET 34
TABLE 5 U.S. INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 35
FIGURE 6 U.S. INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET BY
APPLICATION, MARKET SHARES, 2018 (%) 35
INDUCED PLURIPOTENT STEM CELL-DERIVED TISSUE CELL MARKET 36
TABLE 6 INDUCED PLURIPOTENT STEM CELL-DERIVED TISSUE CELL MARKET BY
TYPE, THROUGH 2018 ($ MILLIONS) 36
FIGURE 7 INDUCED PLURIPOTENT STEM CELL-DERIVED TISSUE CELL MARKET
SHARES BY TYPE, 2018 (%) 37
INDUCED PLURIPOTENT STEM CELL AND DERIVATIVE CELL MARKET 37
TABLE 7 INDUCED PLURIPOTENT STEM CELL AND DERIVATIVE CELL MARKET BY
SPECIES, THROUGH 2018 ($ MILLIONS) 38
MAJOR SUPPLIERS AND MANUFACTURERS OF INDUCED PLURIPOTENT STEM
CELL PRODUCTS 38
TABLE 8 MAJOR COMMERCIAL INDUCED PLURIPOTENT STEM CELL PRODUCT
SUPPLIERS, DECEMBER 31, 2013 38
FIGURE 8 MAJOR COMMERCIAL INDUCED PLURIPOTENT STEM CELL SUPPLIERS BY
COUNTRY, 2013 40
FIGURE 9 MAJOR U.S. COMMERCIAL INDUCED PLURIPOTENT STEM CELL PRODUCT
SUPPLIERS BY STATE, 2013 41
TABLE 9 MAJOR COMMERCIAL INDUCED PLURIPOTENT STEM CELL CELLULAR
PRODUCT MANUFACTURERS, DECEMBER 31, 2013 42
FIGURE 10 MAJOR COMMERCIAL INDUCED PLURIPOTENT STEM CELL PRODUCT
MANUFACTURERS BY COUNTRY, 2013 43
FIGURE 11 MAJOR U.S. COMMERCIAL INDUCED PLURIPOTENT STEM CELL PRODUCT
MANUFACTURERS BY STATE, 2013 43
INDUCED PLURIPOTENT STEM CELL-DERIVED CELL MARKETS BY APPLICATION 44
TABLE 10 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 45
FIGURE 12 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL MARKET SHARES BY
APPLICATION, 2018 (%) 45
INDUCED PLURIPOTENT STEM CELL MARKET BY PRODUCT FUNCTION 46
GLOBAL MARKET 46
TABLE 11 INDUCED PLURIPOTENT STEM CELL-RELATED PRODUCT MARKET BY
PRODUCT FUNCTION, THROUGH 2018 ($ MILLIONS) 46
FIGURE 13 INDUCED PLURIPOTENT STEM CELL MARKET SHARES BY PRODUCT
FUNCTION, 2018 (%) 47
REGIONAL MARKETS 47
TABLE 12 U.S. INDUCED PLURIPOTENT STEM CELL-RELATED PRODUCT MARKETS
BY PRODUCT FUNCTION, THROUGH 2018 ($ MILLIONS) 48
FIGURE 14 U.S. INDUCED PLURIPOTENT STEM CELL MARKET SHARES BY PRODUCT
FUNCTION, 2018 (%) 48
RESEARCH MARKET VERSUS CLINICAL MARKET 49
TABLE 13 INDUCED PLURIPOTENT STEM CELL MARKETS, THROUGH 2018 ($
MILLIONS) 49
FIGURE 15 INDUCED PLURIPOTENT STEM CELL MARKET SHARES, 2018 (%) 50
APPLICATION-BASED MARKETS FOR INDUCED PLURIPOTENT STEM
CELL-DERIVED CELLS 50
HUMAN CARDIOMYOCYTES DERIVED FROM INDUCED PLURIPOTENT STEM
CELLS MARKET 51
Global Market 51
TABLE 14 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN CARDIOMYOCYTE
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 51
FIGURE 16 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN CARDIOMYOCYTE
MARKET SHARES BY APPLICATION, 2018 (%) 51
Regional Markets 52
TABLE 15 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 53
FIGURE 17 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 53
TABLE 16 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 54
FIGURE 18 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 54
TABLE 17 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 56
FIGURE 19 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 56
HUMAN HEPATOCYTES DERIVED FROM INDUCED PLURIPOTENT STEM
CELLS MARKET 57
Global Market 57
TABLE 18 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN HEPATOCYTE
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 57
FIGURE 20 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN HEPATOCYTE
MARKET SHARES BY APPLICATION, 2018 (%) 57
Regional Markets 58
TABLE 19 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN HEPATOCYTE
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 58
FIGURE 21 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN HEPATOCYTE
MARKET SHARES BY APPLICATION, 2018 (%) 58
TABLE 20 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
HEPATOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 60
FIGURE 22 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
HEPATOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 60
TABLE 21 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
HEPATOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 61
FIGURE 23 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
HEPATOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 61
HUMAN ENDOTHELIA CELLS DERIVED FROM INDUCED PLURIPOTENT STEM
CELLS MARKET 62
Global Market 62
TABLE 22 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN ENDOTHELIA CELL
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 62
FIGURE 24 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN ENDOTHELIA CELL
MARKET SHARES BY APPLICATION, 2018 (%) 63
Regional Markets 63
TABLE 23 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN ENDOTHELIA
CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 64
FIGURE 25 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN ENDOTHELIA
CELL MARKET SHARES BY APPLICATION, 2018 (%) 64
TABLE 24 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
ENDOTHELIA CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 65
FIGURE 26 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
ENDOTHELIA CELL MARKET SHARES BY APPLICATION, 2018 (%) 65
TABLE 25 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
ENDOTHELIA CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 66
FIGURE 27 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
ENDOTHELIA CELL MARKET SHARES BY APPLICATION, 2018 (%) 67
HUMAN NEURAL CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELL
MARKET 67
Global Market 67
TABLE 26 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL CELL
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 68
FIGURE 28 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL CELL
MARKET SHARES BY APPLICATION, 2018 (%) 68
Regional Markets 68
TABLE 27 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL CELL
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 69
FIGURE 29 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL CELL
MARKET SHARES BY APPLICATION, 2018 (%) 69
TABLE 28 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
NEURAL CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 70
FIGURE 30 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
NEURAL CELL MARKET SHARES BY APPLICATION, 2018 (%) 70
TABLE 29 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
NEURAL CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 71
FIGURE 31 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
NEURAL CELL MARKET SHARES BY APPLICATION, 2018 (%) 71
INDUCED PLURIPOTENT STEM CELLS AND THEIR DERIVED CELLS MARKET BY
SPECIES 72
GLOBAL MARKET 72
TABLE 30 INDUCED PLURIPOTENT STEM CELL AND DERIVATIVE CELL MARKET BY
SPECIES, THROUGH 2018 ($ MILLIONS) 73
FIGURE 32 INDUCED PLURIPOTENT STEM CELL AND DERIVATIVE CELL MARKET
SHARES BY SPECIES, 2018 (%) 73
REGIONAL MARKETS 74
TABLE 31 U.S. INDUCED PLURIPOTENT STEM CELLS AND DERIVATIVE CELLS
MARKET BY SPECIES, THROUGH 2018 ($ MILLIONS) 74
TABLE 32 EUROPEAN INDUCED PLURIPOTENT STEM CELL AND DERIVATIVE CELL
MARKET BY SPECIES, THROUGH 2018 ($ MILLIONS) 75
TABLE 33 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS AND DERIVATIVE
CELLS MARKET BY SPECIES, THROUGH 2018 ($ MILLIONS) 75
INDUCED PLURIPOTENT STEM CELL CULTURE MARKETS 76
TABLE 34 CELL CULTURE PRODUCTS FOR INDUCED PLURIPOTENT STEM CELLS
AND DERIVED CELLS MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 76
FIGURE 33 INDUCED PLURIPOTENT STEM CELL CULTURE PRODUCT MARKET
SHARES BY REGION, 2018 (%) 76

CHAPTER 6 INDUCED PLURIPOTENT STEM CELL RESEARCH APPLICATION MARKET 79
INDUCED PLURIPOTENT STEM CELL RESEARCH PRODUCT TYPES 79
TABLE 35 INDUCED PLURIPOTENT STEM CELL-RELATED PRODUCT MARKET BY
FUNCTION, THROUGH 2018 ($ MILLIONS) 80
FIGURE 34 INDUCED PLURIPOTENT STEM CELL MARKET SHARES BY PRODUCT
FUNCTION, 2018 (%) 80
TABLE 36 U.S. INDUCED PLURIPOTENT STEM CELL-RELATED PRODUCT MARKET BY
FUNCTION, THROUGH 2018 ($ MILLIONS) 81
FIGURE 35 U.S. INDUCED PLURIPOTENT STEM CELL MARKET SHARES BY PRODUCT
FUNCTION, 2018 (%) 81
TABLE 37 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL PRODUCT MARKET
FOR RESEARCH BY CELL TYPE, THROUGH 2018 ($ MILLIONS) 82
FIGURE 36 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL RESEARCH MARKET
SHARES BY CELL TYPE, 2018 (%) 83
TABLE 38 INDUCED PLURIPOTENT STEM CELL RESEARCH MARKET BY REGION,
THROUGH 2018 ($ MILLIONS) 84
FIGURE 37 INDUCED PLURIPOTENT STEM CELL RESEARCH MARKET SHARES BY
REGION, 2018 (%) 84
MAJOR PLAYERS 85
MAJOR COMMERCIAL ENTITIES 85
MAJOR NON-COMMERCIAL ORGANIZATIONS 85
Top Institutions Performing Induced Pluripotent Stem Cell Research 85
Induced Pluripotent Stem Cell Core Facilities 85
TABLE 39 MAJOR UNIVERSITY AND INSTITUTE INDUCED PLURIPOTENT STEM CELL
CORE FACILITIES BY LOCATION 86
MARKET SHARES AND PROJECTIONS 87

CHAPTER 7 DRUG DISCOVERY AND DEVELOPMENT MARKET 89
PRODUCT TYPES 89
MAJOR PLAYERS 89
MARKET SHARES AND PROJECTIONS 89
TABLE 40 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL PRODUCTS FOR
DRUG DEVELOPMENT AND TOXICITY TESTING MARKET BY CELL TYPE, THROUGH
2018 ($ MILLIONS)
90
FIGURE 38 INDUCED PLURIPOTENT STEM CELL-DRUG DEVELOPMENT AND
TOXICITY TESTING MARKET SHARES BY CELL TYPE, 2018 (%) 90
TABLE 41 INDUCED PLURIPOTENT STEM CELL DRUG DEVELOPMENT AND TOXICITY
TESTING MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 91
FIGURE 39 INDUCED PLURIPOTENT STEM CELL DRUG DEVELOPMENT AND
TOXICITY TESTING MARKET SHARES BY REGION, 2018 (%) 91

CHAPTER 8 INDUCED PLURIPOTENT STEM CELL CONTRACT SERVICE MARKET 94
INDUCED PLURIPOTENT STEM CELL CONTRACT SERVICE TYPES 94
MAJOR PLAYERS 94
TABLE 42 MAJOR COMPANIES PROVIDING INDUCED PLURIPOTENT STEM CELL
CONTRACT SERVICES, 2013 94
MARKET SHARES AND PROJECTIONS 95
TABLE 43 INDUCED PLURIPOTENT STEM CELL CONTRACT SERVICE MARKET BY
REGION, THROUGH 2018 ($ MILLIONS) 95
FIGURE 40 INDUCED PLURIPOTENT STEM CELL SERVICE MARKET SHARES BY
REGION, 2018 (%) 95

CHAPTER 9 INDUCED PLURIPOTENT STEM CELL CLINICAL APPLICATION MARKET 98
PRODUCT TYPES 98
REGULATIONS 98
MARKET PROJECTION 98
TABLE 44 INDUCED PLURIPOTENT STEM CELL PRODUCTS FOR REGENERATIVE
MEDICINE MARKET BY CELL TYPE, THROUGH 2018 ($ MILLIONS) 99
FIGURE 41 INDUCED PLURIPOTENT STEM CELL-DERIVED REGENERATIVE MEDICINE
MARKET SHARES BY CELL TYPE, 2018 (%) 99
TABLE 45 INDUCED PLURIPOTENT STEM CELL CLINICAL MARKETS (INCLUDING
PATIENT-SPECIFIC INDUCED PLURIPOTENT STEM CELL BANKING) BY REGION,
THROUGH 2018 ($ MILLIONS)
100
FIGURE 42 INDUCED PLURIPOTENT STEM CELL CLINICAL MARKET SHARES BY
REGION, 2018 (%) 100

CHAPTER 10 RESEARCH MARKET TREND ANALYSIS 103
GRANT ANALYSIS 103
TABLE 46 MAJOR GOVERNMENTAL INDUCED PLURIPOTENT STEM CELL RESEARCH
FUNDING BY REGION, 2007-2013 ($ MILLIONS/%) 103
FIGURE 43 GOVERNMENTAL INDUCED PLURIPOTENT STEM CELL RESEARCH
FUNDING BY REGION, 2007-2013 (%) 104
TABLE 47 NATIONAL INSTITUTES OF HEALTH INDUCED PLURIPOTENT STEM CELL
RESEARCH FUNDING, 2007-2013 (NUMBER OF GRANTS/$ MILLIONS) 104
FIGURE 44 NATIONAL INSTITUTES OF HEALTH INDUCED PLURIPOTENT STEM CELL
RESEARCH FUNDING, 2007-2013 ($ MILLIONS) 104
TABLE 48 CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE INDUCED
PLURIPOTENT STEM CELL FUNDING, INCLUDING DIRECTLY REPROGRAMMED CELLS,
THROUGH DECEMBER 24, 2013 (NUMBER/$ MILLIONS)
105
PATENT ANALYSIS 105
TABLE 49 INDUCED PLURIPOTENT STEM CELL PATENTS ISSUED BY THE U.S.
PATENT AND TRADEMARK OFFICE, TO DECEMBER 2013 106
TABLE 50 U.S. PATENT AND TRADEMARK OFFICE-ISSUED PATENTS BY REGION, TO
DECEMBER 2013 (NUMBER/%) 107
TABLE 51 INDUCED PLURIPOTENT STEM CELL PATENT AND PATENT APPLICATION
DISTRIBUTION BY FILING OFFICE OR COUNTRY (NUMBER/%) 108
FIGURE 45 INDUCED PLURIPOTENT STEM CELL PATENT AND PATENT APPLICATION
DISTRIBUTION BY FILING OFFICE OR COUNTRY (NUMBER) 108
TABLE 52 GLOBAL INDUCED PLURIPOTENT STEM CELL PATENTS OR PATENT
APPLICATIONS (NUMBER/%) 109
TABLE 53 GLOBAL INDUCED PLURIPOTENT STEM CELL PATENT APPLICATIONS,
DECEMBER 31, 2014 (NUMBER/%) 109
TABLE 54 WORLD INTELLECTUAL PROPERTY OFFICE INDUCED PLURIPOTENT STEM
CELL PATENT PUBLICATIONS BY YEAR, 2007-2013 (NUMBER) 110
FIGURE 46 WORLD INTELLECTUAL PROPERTY OFFICE INDUCED PLURIPOTENT STEM
CELL PATENT APPLICATIONS, 2007-2013 (NUMBER) 110
TABLE 55 U.S. PATENT AND TRADEMARK OFFICE INDUCED PLURIPOTENT STEM
CELL PATENT APPLICATION TRENDS, 2009-2013 (NUMBER) 111
FIGURE 47 U.S. PATENT AND TRADEMARK OFFICE INDUCED PLURIPOTENT STEM
CELL PATENT APPLICATION TRENDS, 2009-2013 (NUMBER) 111
TABLE 56 GLOBAL INDUCED PLURIPOTENT STEM CELL PATENT AND PATENT
APPLICATION DISTRIBUTION, THROUGH 2013 (NUMBER OF PATENTS/%) 112
TABLE 57 U.S. INDUCED PLURIPOTENT STEM CELL PATENTS AND PATENT
APPLICATIONS BY STATE, THROUGH 2013 (NUMBER/%) 112
TABLE 58 WORLD INTELLECTUAL PROPERTY ORGANIZATION INDUCED
PLURIPOTENT STEM CELL PATENT PUBLICATIONS BY CATEGORY, THROUGH 2013
(NUMBER/%)
113
SCIENTIFIC PUBLICATION ANALYSIS 113
TABLE 59 INDUCED PLURIPOTENT STEM CELL PUBLICATIONS, 2006-2013 (NUMBER) 114
FIGURE 48 INDUCED PLURIPOTENT STEM CELL PUBLICATIONS, 2006-2013
(NUMBER) 114
DRIVING FORCES 114

CHAPTER 11 CLINICAL MARKET TREND ANALYSIS 117
CLINICAL TRIALS 117
DRIVING FORCES 117
LIMITING FACTORS 118
TECHNOLOGIES 118
REGULATIONS 118
MARKET ACCEPTANCE 119
CLINICAL EFFICIENCY 119

CHAPTER 12 COMPANY PROFILES 121
AXIOGENESIS AG 121
CELLECTICS 121
CELLULAR DYNAMICS INC. 122
FATE THERAPEUTICS 122
IPERIAN 123
LONZA 123
REPROCELL INC. 123
STEMGENT INC. 124
SYSTEM BIOSCIENCES INC. 124
VIACYTE 125
WAISMAN BIOMANUFACTURING 125
CHAPTER 13 CONCLUSIONS 127


LIST OF TABLES


SUMMARY TABLE GLOBAL INDUCED PLURIPOTENT STEM CELL MARKET BY REGION,
THROUGH 2018 ($ MILLIONS) 7
TABLE 1 U.S. INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET BY STATE,
THROUGH 2018 ($ MILLIONS) 29
TABLE 2 METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS,
THROUGH 2018 ($ MILLIONS) 31
TABLE 3 METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS,
THROUGH 2018 ($ MILLIONS) 32
TABLE 4 GLOBAL INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 33
TABLE 5 U.S. INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 35
TABLE 6 INDUCED PLURIPOTENT STEM CELL-DERIVED TISSUE CELL MARKET BY TYPE,
THROUGH 2018 ($ MILLIONS) 36
TABLE 7 INDUCED PLURIPOTENT STEM CELL AND DERIVATIVE CELL MARKET BY
SPECIES, THROUGH 2018 ($ MILLIONS) 38
TABLE 8 MAJOR COMMERCIAL INDUCED PLURIPOTENT STEM CELL PRODUCT
SUPPLIERS, DECEMBER 31, 2013 38
TABLE 9 MAJOR COMMERCIAL INDUCED PLURIPOTENT STEM CELL CELLULAR
PRODUCT MANUFACTURERS, DECEMBER 31, 2013 42
TABLE 10 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL MARKET BY
APPLICATION, THROUGH 2018 ($ MILLIONS) 45
TABLE 11 INDUCED PLURIPOTENT STEM CELL-RELATED PRODUCT MARKET BY
PRODUCT FUNCTION, THROUGH 2018 ($ MILLIONS) 46
TABLE 12 U.S. INDUCED PLURIPOTENT STEM CELL-RELATED PRODUCT MARKETS BY
PRODUCT FUNCTION, THROUGH 2018 ($ MILLIONS) 48
TABLE 13 INDUCED PLURIPOTENT STEM CELL MARKETS, THROUGH 2018 ($
MILLIONS) 49
TABLE 14 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN CARDIOMYOCYTE
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 51
TABLE 15 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 53
TABLE 16 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 54
TABLE 17 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 56
TABLE 18 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN HEPATOCYTE
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 57
TABLE 19 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN HEPATOCYTE
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 58
TABLE 20 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
HEPATOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 60
TABLE 21 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
HEPATOCYTE MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 61
TABLE 22 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN ENDOTHELIA CELL
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 62
TABLE 23 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN ENDOTHELIA
CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 64
TABLE 24 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
ENDOTHELIA CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 65
TABLE 25 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
ENDOTHELIA CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 66
TABLE 26 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL CELL
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 68
TABLE 27 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL CELL
MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 69
TABLE 28 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL
CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 70
TABLE 29 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
NEURAL CELL MARKET BY APPLICATION, THROUGH 2018 ($ MILLIONS) 71
TABLE 30 INDUCED PLURIPOTENT STEM CELL AND DERIVATIVE CELL MARKET BY
SPECIES, THROUGH 2018 ($ MILLIONS) 73
TABLE 31 U.S. INDUCED PLURIPOTENT STEM CELLS AND DERIVATIVE CELLS MARKET
BY SPECIES, THROUGH 2018 ($ MILLIONS) 74
TABLE 32 EUROPEAN INDUCED PLURIPOTENT STEM CELL AND DERIVATIVE CELL
MARKET BY SPECIES, THROUGH 2018 ($ MILLIONS) 75
TABLE 33 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELLS AND DERIVATIVE CELLS
MARKET BY SPECIES, THROUGH 2018 ($ MILLIONS) 75
TABLE 34 CELL CULTURE PRODUCTS FOR INDUCED PLURIPOTENT STEM CELLS AND
DERIVED CELLS MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 76
TABLE 35 INDUCED PLURIPOTENT STEM CELL-RELATED PRODUCT MARKET BY
FUNCTION, THROUGH 2018 ($ MILLIONS) 80
TABLE 36 U.S. INDUCED PLURIPOTENT STEM CELL-RELATED PRODUCT MARKET BY
FUNCTION, THROUGH 2018 ($ MILLIONS) 81
TABLE 37 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL PRODUCT MARKET FOR
RESEARCH BY CELL TYPE, THROUGH 2018 ($ MILLIONS) 82
TABLE 38 INDUCED PLURIPOTENT STEM CELL RESEARCH MARKET BY REGION,
THROUGH 2018 ($ MILLIONS) 84
TABLE 39 MAJOR UNIVERSITY AND INSTITUTE INDUCED PLURIPOTENT STEM CELL
CORE FACILITIES BY LOCATION 86
TABLE 40 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL PRODUCTS FOR DRUG
DEVELOPMENT AND TOXICITY TESTING MARKET BY CELL TYPE, THROUGH 2018 ($
MILLIONS)
90
TABLE 41 INDUCED PLURIPOTENT STEM CELL DRUG DEVELOPMENT AND TOXICITY
TESTING MARKET BY REGION, THROUGH 2018 ($ MILLIONS) 91
TABLE 42 MAJOR COMPANIES PROVIDING INDUCED PLURIPOTENT STEM CELL
CONTRACT SERVICES, 2013 94
TABLE 43 INDUCED PLURIPOTENT STEM CELL CONTRACT SERVICE MARKET BY
REGION, THROUGH 2018 ($ MILLIONS) 95
TABLE 44 INDUCED PLURIPOTENT STEM CELL PRODUCTS FOR REGENERATIVE
MEDICINE MARKET BY CELL TYPE, THROUGH 2018 ($ MILLIONS) 99
TABLE 45 INDUCED PLURIPOTENT STEM CELL CLINICAL MARKETS (INCLUDING
PATIENT-SPECIFIC INDUCED PLURIPOTENT STEM CELL BANKING) BY REGION,
THROUGH 2018 ($ MILLIONS)
100
TABLE 46 MAJOR GOVERNMENTAL INDUCED PLURIPOTENT STEM CELL RESEARCH
FUNDING BY REGION, 2007-2013 ($ MILLIONS/%) 103
TABLE 47 NATIONAL INSTITUTES OF HEALTH INDUCED PLURIPOTENT STEM CELL
RESEARCH FUNDING, 2007-2013 (NUMBER OF GRANTS/$ MILLIONS) 104
TABLE 48 CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE INDUCED
PLURIPOTENT STEM CELL FUNDING, INCLUDING DIRECTLY REPROGRAMMED CELLS,
THROUGH DECEMBER 24, 2013 (NUMBER/$ MILLIONS)
105
TABLE 49 INDUCED PLURIPOTENT STEM CELL PATENTS ISSUED BY THE U.S. PATENT
AND TRADEMARK OFFICE, TO DECEMBER 2013 106
TABLE 50 U.S. PATENT AND TRADEMARK OFFICE-ISSUED PATENTS BY REGION, TO
DECEMBER 2013 (NUMBER/%) 107
TABLE 51 INDUCED PLURIPOTENT STEM CELL PATENT AND PATENT APPLICATION
DISTRIBUTION BY FILING OFFICE OR COUNTRY (NUMBER/%) 108
TABLE 52 GLOBAL INDUCED PLURIPOTENT STEM CELL PATENTS OR PATENT
APPLICATIONS (NUMBER/%) 109
TABLE 53 GLOBAL INDUCED PLURIPOTENT STEM CELL PATENT APPLICATIONS,
DECEMBER 31, 2014 (NUMBER/%) 109
TABLE 54 WORLD INTELLECTUAL PROPERTY OFFICE INDUCED PLURIPOTENT STEM
CELL PATENT PUBLICATIONS BY YEAR, 2007-2013 (NUMBER) 110
TABLE 55 U.S. PATENT AND TRADEMARK OFFICE INDUCED PLURIPOTENT STEM CELL
PATENT APPLICATION TRENDS, 2009-2013 (NUMBER) 111
TABLE 56 GLOBAL INDUCED PLURIPOTENT STEM CELL PATENT AND PATENT
APPLICATION DISTRIBUTION, THROUGH 2013 (NUMBER OF PATENTS/%) 112
TABLE 57 U.S. INDUCED PLURIPOTENT STEM CELL PATENTS AND PATENT
APPLICATIONS BY STATE, THROUGH 2013 (NUMBER/%) 112
TABLE 58 WORLD INTELLECTUAL PROPERTY ORGANIZATION INDUCED PLURIPOTENT
STEM CELL PATENT PUBLICATIONS BY CATEGORY, THROUGH 2013 (NUMBER/%) 113
TABLE 59 INDUCED PLURIPOTENT STEM CELL PUBLICATIONS, 2006-2013 (NUMBER) 114


LIST OF FIGURES


SUMMARY FIGURE GLOBAL INDUCED PLURIPOTENT STEM CELL MARKET BY REGION,
2012-2018 ($ MILLIONS) 7
FIGURE 1 GLOBAL INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET SHARES
BY REGION, 2018 (%) 28
FIGURE 2 U.S. INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET SHARES BY
STATE, 2018 (%) 29
FIGURE 3 METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELLS,
MARKET SHARES, 2018 (%) 31
FIGURE 4 METHODS FOR GENERATING INDUCED PLURIPOTENT STEM CELL, MARKET
SHARES, 2018 (%) 32
FIGURE 5 GLOBAL INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET SHARES
BY APPLICATION, 2018 (%) 33
FIGURE 6 U.S. INDUCED PLURIPOTENT STEM CELL PRODUCT MARKET BY
APPLICATION, MARKET SHARES, 2018 (%) 35
FIGURE 7 INDUCED PLURIPOTENT STEM CELL-DERIVED TISSUE CELL MARKET
SHARES BY TYPE, 2018 (%) 37
FIGURE 8 MAJOR COMMERCIAL INDUCED PLURIPOTENT STEM CELL SUPPLIERS BY
COUNTRY, 2013 40
FIGURE 9 MAJOR U.S. COMMERCIAL INDUCED PLURIPOTENT STEM CELL PRODUCT
SUPPLIERS BY STATE, 2013 41
FIGURE 10 MAJOR COMMERCIAL INDUCED PLURIPOTENT STEM CELL PRODUCT
MANUFACTURERS BY COUNTRY, 2013 43
FIGURE 11 MAJOR U.S. COMMERCIAL INDUCED PLURIPOTENT STEM CELL PRODUCT
MANUFACTURERS BY STATE, 2013 43
FIGURE 12 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL MARKET SHARES BY
APPLICATION, 2018 (%) 45
FIGURE 13 INDUCED PLURIPOTENT STEM CELL MARKET SHARES BY PRODUCT
FUNCTION, 2018 (%) 47
FIGURE 14 U.S. INDUCED PLURIPOTENT STEM CELL MARKET SHARES BY PRODUCT
FUNCTION, 2018 (%) 48
FIGURE 15 INDUCED PLURIPOTENT STEM CELL MARKET SHARES, 2018 (%) 50
FIGURE 16 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN CARDIOMYOCYTE
MARKET SHARES BY APPLICATION, 2018 (%) 51
FIGURE 17 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 53
FIGURE 18 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 54
FIGURE 19 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
CARDIOMYOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 56
FIGURE 20 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN HEPATOCYTE
MARKET SHARES BY APPLICATION, 2018 (%) 57
FIGURE 21 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN HEPATOCYTE
MARKET SHARES BY APPLICATION, 2018 (%) 58
FIGURE 22 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
HEPATOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 60
FIGURE 23 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
HEPATOCYTE MARKET SHARES BY APPLICATION, 2018 (%) 61
FIGURE 24 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN ENDOTHELIA CELL
MARKET SHARES BY APPLICATION, 2018 (%) 63
FIGURE 25 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN ENDOTHELIA
CELL MARKET SHARES BY APPLICATION, 2018 (%) 64
FIGURE 26 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
ENDOTHELIA CELL MARKET SHARES BY APPLICATION, 2018 (%) 65
FIGURE 27 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
ENDOTHELIA CELL MARKET SHARES BY APPLICATION, 2018 (%) 67
FIGURE 28 INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL CELL
MARKET SHARES BY APPLICATION, 2018 (%) 68
FIGURE 29 U.S. INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL CELL
MARKET SHARES BY APPLICATION, 2018 (%) 69
FIGURE 30 EUROPEAN INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN NEURAL
CELL MARKET SHARES BY APPLICATION, 2018 (%) 70
FIGURE 31 ASIA-PACIFIC INDUCED PLURIPOTENT STEM CELL-DERIVED HUMAN
NEURAL CELL MARKET SHARES BY APPLICATION, 2018 (%) 71
FIGURE 32 INDUCED PLURIPOTENT STEM CELL AND DERIVATIVE CELL MARKET
SHARES BY SPECIES, 2018 (%) 73
FIGURE 33 INDUCED PLURIPOTENT STEM CELL CULTURE PRODUCT MARKET SHARES
BY REGION, 2018 (%) 76
FIGURE 34 INDUCED PLURIPOTENT STEM CELL MARKET SHARES BY PRODUCT
FUNCTION, 2018 (%) 80
FIGURE 35 U.S. INDUCED PLURIPOTENT STEM CELL MARKET SHARES BY PRODUCT
FUNCTION, 2018 (%) 81
FIGURE 36 INDUCED PLURIPOTENT STEM CELL-DERIVED CELL RESEARCH MARKET
SHARES BY CELL TYPE, 2018 (%) 83
FIGURE 37 INDUCED PLURIPOTENT STEM CELL RESEARCH MARKET SHARES BY
REGION, 2018 (%) 84
FIGURE 38 INDUCED PLURIPOTENT STEM CELL-DRUG DEVELOPMENT AND TOXICITY
TESTING MARKET SHARES BY CELL TYPE, 2018 (%) 90
FIGURE 39 INDUCED PLURIPOTENT STEM CELL DRUG DEVELOPMENT AND TOXICITY
TESTING MARKET SHARES BY REGION, 2018 (%) 91
FIGURE 40 INDUCED PLURIPOTENT STEM CELL SERVICE MARKET SHARES BY
REGION, 2018 (%) 95
FIGURE 41 INDUCED PLURIPOTENT STEM CELL-DERIVED REGENERATIVE MEDICINE
MARKET SHARES BY CELL TYPE, 2018 (%) 99
FIGURE 42 INDUCED PLURIPOTENT STEM CELL CLINICAL MARKET SHARES BY
REGION, 2018 (%) 100
FIGURE 43 GOVERNMENTAL INDUCED PLURIPOTENT STEM CELL RESEARCH
FUNDING BY REGION, 2007-2013 (%) 104
FIGURE 44 NATIONAL INSTITUTES OF HEALTH INDUCED PLURIPOTENT STEM CELL
RESEARCH FUNDING, 2007-2013 ($ MILLIONS) 104
FIGURE 45 INDUCED PLURIPOTENT STEM CELL PATENT AND PATENT APPLICATION
DISTRIBUTION BY FILING OFFICE OR COUNTRY (NUMBER) 108
FIGURE 46 WORLD INTELLECTUAL PROPERTY OFFICE INDUCED PLURIPOTENT STEM
CELL PATENT APPLICATIONS, 2007-2013 (NUMBER) 110
FIGURE 47 U.S. PATENT AND TRADEMARK OFFICE INDUCED PLURIPOTENT STEM
CELL PATENT APPLICATION TRENDS, 2009-2013 (NUMBER) 111
FIGURE 48 INDUCED PLURIPOTENT STEM CELL PUBLICATIONS, 2006-2013 (NUMBER) 114


Read the full report:
Induced Pluripotent Stem Cells : Global Markets

https://www.reportbuyer.com/product/2212008/Induced-Pluripotent-Stem-Cells--Global-Markets.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow